Stockreport

Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF and efficacy of its lead candidate, REC-994, an orally bioavailable, superoxide scavenger small molecule, for symptomatic cerebral cavernous malformation (CCM) patients. [Read more]